Leviosa (Dexamethasone, Levofloxacin)

Dexamethasone acts on glucocorticoid receptors to suppress inflammatory mediators, reducing swelling and redness in the eye. Levofloxacin penetrates bacterial cells and blocks DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, resulting in bactericidal activity. Together they provide simultaneous control of inflammation and infection.

The dosing regimen for Leviosa is determined by the prescribing ophthalmologist based on the severity of the condition, patient age, and response to therapy. The prescriber will specify the number of drops, frequency, and duration of treatment.

Safety data for Leviosa in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when appropriate. If treatment is deemed necessary, it should be used under close medical supervision.

To request Leviosa, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements) and required import documentation.

Compared with separate dexamethasone eye drops and fluoroquinolone antibiotics, Leviosa offers the convenience of a single formulation that delivers both anti‑inflammatory and antibacterial effects. This can improve patient adherence and reduce the need for multiple bottles, while maintaining comparable efficacy and safety profiles to the individual agents.

Leviosa should be stored below 25 °C in its original container, protected from light and moisture. Do not freeze the product. Keep the vial tightly closed when not in use and discard any solution that appears discolored or contaminated.

Leviosa is applied topically to the eye as directed by the prescriber. Typically, one or more drops are placed into the affected eye(s) at the prescribed interval. Patients should wash their hands before and after administration and avoid touching the tip of the bottle to the ocular surface.

Serious risks include severe allergic reactions (anaphylaxis), significant elevation of intra‑ocular pressure that may lead to glaucoma, corneal ulceration, development of resistant bacterial strains, and, with prolonged use, cataract formation. Patients should be monitored regularly for these events, especially if therapy extends beyond the recommended duration.

Leviosa is contraindicated in patients with known hypersensitivity to dexamethasone, levofloxacin, other corticosteroids, or fluoroquinolones. It should also be avoided in viral, fungal, or amoebic eye infections, as corticosteroids can exacerbate these conditions. Caution is advised in individuals with uncontrolled glaucoma or a history of steroid‑responsive intra‑ocular pressure elevation.